AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33160636 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfibrillar collagen hemostat
Number of subjects: 203
Study 33160636 — intervention group
Group type: COMPARATOR
Intervention: No microfibrillar collagen hemostat
Number of subjects: 203
Study 33109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants (150 species)
Number of subjects: 79
Study 33109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants for digestive disorders
Number of subjects: 79
Study 33109243 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal plants with 100% fidelity values
Number of subjects: 79
Study 33109243 — intervention group
Group type: COMPARATOR
Intervention: Comparison of plant uses
Number of subjects: 79
Study 33037580 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydration with/without cinacalcet
Number of subjects: 8
Study 33037580 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol ablation of the parathyroid adenoma
Number of subjects: 8
Study 33037580 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vaginal delivery at term
Number of subjects: 8
Study 33037580 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal outcomes
Number of subjects: 8
Study 33037580 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 8
Study 32317470 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 60
Study 32317470 — intervention group
Group type: COMPARATOR
Intervention: Inverted internal limiting membrane (ILM) flap
Number of subjects: 60
Study 35237893 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin (AST) 8 mg daily for 40 days
Number of subjects: 0
Study 35237893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35468827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' educational program (individual face-to-face education and counseling, 2 sessions, 40 min each, 1-week interval)
Number of subjects: 76
Study 35468827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education for fathers, only mothers educated)
Number of subjects: 76
Study 35468827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers' educational program
Number of subjects: 76
Study 34529963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (5×10^10 viral particles) on day 1 followed by MVA-BN-Filo (1×10^8 infectious units) on day 57
Number of subjects: 443
Study 34529963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV (5×10^10 viral particles) followed by MVA-BN-Filo
Number of subjects: 443
Study 34529963 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV followed by MVA-BN-Filo
Number of subjects: 443
Study 34529963 — intervention group
Group type: COMPARATOR
Intervention: MenACWY (first dose) followed by placebo (second dose)
Number of subjects: 443
Study 34529963 — intervention group
Group type: COMPARATOR
Intervention: MenACWY
Number of subjects: 443
Study 35858497 — intervention group
Group type: EXPERIMENTAL
Intervention: Primarily overt stuttering
Number of subjects: 21
Study 35858497 — intervention group
Group type: EXPERIMENTAL
Intervention: Primarily covert stuttering
Number of subjects: 21
Study 35858497 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 21
Study 34493413 — intervention group
Group type: EXPERIMENTAL
Intervention: Predict Prostate tool
Number of subjects: 145
Study 34493413 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 145
Study 35501178 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 (5 μg SARS-CoV-2 rS; 50 μg Matrix-M1)
Number of subjects: 200
Study 35501178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 35501178 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 200
Study 33819703 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based radiomic model using XGBoost
Number of subjects: 109
Study 33819703 — intervention group
Group type: COMPARATOR
Intervention: Conventional MRI sequences (T1-W, T2-W, T2-FLAIR, post-contrast T1-W, ADC maps)
Number of subjects: 109
Study 33164276 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan (25 mg twice daily for 24 months)
Number of subjects: 64
Study 33164276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33164276 — intervention group
Group type: EXPERIMENTAL
Intervention: Emricasan (25 mg twice daily for 24 months) in F3 to F5 subgroup
Number of subjects: 64
Study 33164276 — intervention group
Group type: COMPARATOR
Intervention: Placebo in F3 to F5 subgroup
Number of subjects: 64
Study 32191001 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity-shockwave therapy (Li-ESWT), 6 sessions over three weeks
Number of subjects: 118
Study 32191001 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium suppositories
Number of subjects: 118
Study 35759368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition + Exercise intervention (individualized high dairy protein diet and walking program)
Number of subjects: 203
Study 35759368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition + Exercise intervention
Number of subjects: 203
Study 35759368 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 203
Study 34899419 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamified AACTP smartphone application + treatment as usual (TAU)
Number of subjects: 317
Study 34899419 — intervention group
Group type: COMPARATOR
Intervention: Gamified AACTP sham-control application + TAU
Number of subjects: 317
Study 34899419 — intervention group
Group type: COMPARATOR
Intervention: Only TAU
Number of subjects: 317
Study 36173219 — intervention group
Group type: EXPERIMENTAL
Intervention: RASM
Number of subjects: 63
Study 36173219 — intervention group
Group type: EXPERIMENTAL
Intervention: ASMI
Number of subjects: 63
Study 36173219 — intervention group
Group type: COMPARATOR
Intervention: L3 SMI
Number of subjects: 63
Study 33890388 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 40 mg/day
Number of subjects: 483
Study 33890388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study 32894140 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate before and whey protein hydrolysate plus carbohydrate after each exercise session (PRO-CHO)
Number of subjects: 24
Study 32894140 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric carbohydrate supplements (CHO)
Number of subjects: 24
Study 33339758 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation and transcranial direct current stimulation
Number of subjects: 36
Study 33339758 — intervention group
Group type: COMPARATOR
Intervention: Vestibular rehabilitation alone
Number of subjects: 36
Study 33487516 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid Court REACH intervention
Number of subjects: 0
Study 35129580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group (individualized sleep hygiene counseling session to extend bedtime to 8.5 hours)
Number of subjects: 80
Study 35129580 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension group
Number of subjects: 80
Study 35129580 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued habitual sleep)
Number of subjects: 80
Study 33663075 — intervention group
Group type: EXPERIMENTAL
Intervention: Buyang Huanwu decoction
Number of subjects: 0
Study 33663075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33753535 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 33037200 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid withdrawal
Number of subjects: 62
Study 36380326 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat-group-based parental health education
Number of subjects: 365
Study 33307024 — intervention group
Group type: COMPARATOR
Intervention: Control group (invitation to screening colonoscopy only)
Number of subjects: 12485
Study 33307024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential group (invitation to primary colonoscopy and invitation for FIT for initial nonresponders)
Number of subjects: 12485
Study 33307024 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group (invitation offering a choice of colonoscopy or FIT)
Number of subjects: 12485
Study 33307024 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12485
Study 33307024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential group
Number of subjects: 12485
Study 33307024 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice group
Number of subjects: 12485
Study 32299386 — intervention group
Group type: EXPERIMENTAL
Intervention: Social concerns related to HIV status disclosure
Number of subjects: 437
Study 32299386 — intervention group
Group type: EXPERIMENTAL
Intervention: Older women (35-44 years)
Number of subjects: 437
Study 32299386 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about isolation or lack of support from family or friends
Number of subjects: 437
Study 32299386 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about separation
Number of subjects: 437
Study 32299386 — intervention group
Group type: EXPERIMENTAL
Intervention: Concern about conflict with a partner
Number of subjects: 437
Study 36208314 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5/6 Fr semi-rigid ureteroscope
Number of subjects: 198
Study 36208314 — intervention group
Group type: COMPARATOR
Intervention: 6/7.5 Fr semi-rigid ureteroscope
Number of subjects: 198
Study 33145855 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended lymph node dissection up to the level of the inferior mesenteric artery
Number of subjects: 0
Study 33145855 — intervention group
Group type: COMPARATOR
Intervention: Lymph node dissection below the bifurcation of the common iliac artery
Number of subjects: 0
Study 33735809 — intervention group
Group type: EXPERIMENTAL
Intervention: ipilimumab plus nivolumab
Number of subjects: 7
Study 32393193 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT)
Number of subjects: 60
Study 32393193 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Number of subjects: 60
Study 36096864 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 400
Study 34394935 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (bicycle ergometric training, 6 times/week for 20 min during a 3-week program)
Number of subjects: 120
Study 34394935 — intervention group
Group type: COMPARATOR
Intervention: Continuous training (bicycle ergometric training, 6 times/week for 20 min during a 3-week program)
Number of subjects: 120
Study 34394935 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interval and continuous training
Number of subjects: 120
Study 35138335 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant ipilimumab plus nivolumab for 6 weeks
Number of subjects: 82
Study 34033935 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 150 µM methylene blue for 2 minutes and a 660 nm wavelength laser for 3 minutes (100 mW, 600 J/cm², total 18J)
Number of subjects: 70
Study 34033935 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) without PDT application
Number of subjects: 70
Study 34033935 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 70
Study 34033935 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 70
Study 33190149 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence to clinical trial protocol
Number of subjects: 1650
Study 33190149 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in optional study DNA collection
Number of subjects: 1650
Study 33190149 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in blood repository studies
Number of subjects: 1650
Study 35878732 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g resistant starch (RS) daily
Number of subjects: 918
Study 35878732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 918
Study 34284064 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning exercise (amEX)
Number of subjects: 40
Study 34284064 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening exercise (pmEX)
Number of subjects: 40
Study 34284064 — intervention group
Group type: COMPARATOR
Intervention: Both amEX and pmEX
Number of subjects: 40
Study 35028968 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful Helicobacter pylori eradication
Number of subjects: 60
Study 35038415 — intervention group
Group type: EXPERIMENTAL
Intervention: Brolucizumab 6 mg
Number of subjects: 926
Study 35038415 — intervention group
Group type: COMPARATOR
Intervention: Brolucizumab 3 mg
Number of subjects: 926
Study 35038415 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 926
Study 33775019 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with sunflower oil (emollient therapy)
Number of subjects: 140
Study 33775019 — intervention group
Group type: COMPARATOR
Intervention: Massage without any emollient (control)
Number of subjects: 140
Study 35247922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab 8 mg/kg biweekly
Number of subjects: 542
Study 35247922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 542
Study 32882569 — intervention group
Group type: EXPERIMENTAL
Intervention: New-generation drug-eluting stents (DES)
Number of subjects: 671
Study 35934913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (1–2 g d1–5) with cytarabine (1 g/m2/2 h b.i.d. d1–5) and daunorubicin (60 mg/m2 d1–3)
Number of subjects: 9
Study 35934913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (1 g)
Number of subjects: 9
Study 35934913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo drug sensitivity assays
Number of subjects: 9
Study 35934913 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea with standard chemotherapy
Number of subjects: 9
Study 36332946 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency-assisted transection (RFT)
Number of subjects: 112
Study 36332946 — intervention group
Group type: COMPARATOR
Intervention: Classic stapler transections (control group)
Number of subjects: 112
Study 35867022 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion for 3 days after transplant
Number of subjects: 50
Study 35867022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32378261 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 74
Study 36195878 — intervention group
Group type: EXPERIMENTAL
Intervention: MPA + HMG
Number of subjects: 300
Study 36195878 — intervention group
Group type: COMPARATOR
Intervention: GnRHa
Number of subjects: 300
Study 32572955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oleoylethanolamide (OEA) supplementation
Number of subjects: 76
Study 32572955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 36324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal Care
Number of subjects: 723
Study 36324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal Leisure Activities
Number of subjects: 723
Study 36324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Related Leisure Time
Number of subjects: 723
Study 36324159 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal Direct Care
Number of subjects: 723
Study 32351591 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week moderate-intensity continuous aerobic exercise program with standard medical treatment
Number of subjects: 31
Study 32351591 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment without any exercise program
Number of subjects: 31
Study 35920294 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training during ketogenic diet (AT-KD)
Number of subjects: 36
Study 35920294 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training during ketogenic diet (RT-KD)
Number of subjects: 36
Study 35920294 — intervention group
Group type: COMPARATOR
Intervention: Ketogenic diet (KD)
Number of subjects: 36
Study 36227064 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group (microsurgical sub-inguinal varicocelectomy)
Number of subjects: 274
Study 36227064 — intervention group
Group type: COMPARATOR
Intervention: Observed group
Number of subjects: 274
Study 36227064 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery group
Number of subjects: 274
Study 32399866 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative DFT testing (n=33)
Number of subjects: 67
Study 32399866 — intervention group
Group type: COMPARATOR
Intervention: Non-intraoperative DFT testing (n=34)
Number of subjects: 67
Study 32399866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study 33171199 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR brachytherapy (125.0 Gy in a single fraction)
Number of subjects: 337
Study 33171199 — intervention group
Group type: COMPARATOR
Intervention: SBRT (42.5 Gy in 5 fractions)
Number of subjects: 337
Study 33171199 — intervention group
Group type: EXPERIMENTAL
Intervention: LDR brachytherapy
Number of subjects: 337
Study 33171199 — intervention group
Group type: COMPARATOR
Intervention: SBRT
Number of subjects: 337
Study 36142070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds (3 capsules daily, 2 in the morning and 1 in the evening)
Number of subjects: 262
Study 36142070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds (3 capsules every 12 hours)
Number of subjects: 262
Study 36142070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa seeds (5 capsules in the morning and 4 in the evening)
Number of subjects: 262
Study 36142070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa powder (1 capsule every 12 hours)
Number of subjects: 262
Study 36142070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa powder (2 capsules every 12 hours)
Number of subjects: 262
Study 36142070 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa powder (3 capsules every 12 hours)
Number of subjects: 262
Study 36142070 — intervention group
Group type: COMPARATOR
Intervention: Charcoal capsules (control group)
Number of subjects: 262
Study 33527863 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiwifruit extract added to standard wound dressing
Number of subjects: 18
Study 33527863 — intervention group
Group type: COMPARATOR
Intervention: Base ointment (Eucerin) for daily wound dressing
Number of subjects: 18
Study 34110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiation therapy (IFRT)
Number of subjects: 549
Study 34110925 — intervention group
Group type: COMPARATOR
Intervention: Posterior fossa radiation therapy (PFRT)
Number of subjects: 549
Study 34110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal irradiation (LDCSI; 18 Gy)
Number of subjects: 549
Study 34110925 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose craniospinal irradiation (SDCSI; 23.4 Gy)
Number of subjects: 549
Study 34110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiation therapy (IFRT) in Sonic Hedgehog MB
Number of subjects: 549
Study 34110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose craniospinal irradiation (LDCSI) in group 4 MB
Number of subjects: 549
Study 34110925 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose craniospinal irradiation (SDCSI)
Number of subjects: 549
Study 32001783 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at 30 Hz, 1.5 mm
Number of subjects: 36
Study 32001783 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control condition)
Number of subjects: 36
Study 34799753 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling (ECC)
Number of subjects: 20
Study 34799753 — intervention group
Group type: COMPARATOR
Intervention: Concentric cycling (CONC)
Number of subjects: 20
Study 34509304 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 375
Study 34509304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 375
Study 34528122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus, 1 mg/kg infusion for first 30 min, followed by 0.5 mg/kg infusion for further 30 min)
Number of subjects: 100
Study 34528122 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 100
Study 34528122 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (50 mg dexketoprofen trometamol and saline)
Number of subjects: 100
Study 34902568 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed outreach for surveillance ultrasound
Number of subjects: 1436
Study 34902568 — intervention group
Group type: COMPARATOR
Intervention: Usual care with visit‐based surveillance
Number of subjects: 1436
Study 33638216 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisional restoration with connective tissue graft (CTG)
Number of subjects: 59
Study 33638216 — intervention group
Group type: COMPARATOR
Intervention: Immediate provisional restoration without connective tissue graft (CTG)
Number of subjects: 59
Study 33638216 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Test and Control)
Number of subjects: 59
Study 32385815 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (CA) treatment (5 mM) under Ni stress
Number of subjects: 0
Study 32385815 — intervention group
Group type: COMPARATOR
Intervention: Nickel (Ni) treatment alone
Number of subjects: 0
Study 32385815 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid (CA) treatment under Ni stress
Number of subjects: 0
Study 35820778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of anal NG infections
Number of subjects: 221
Study 35820778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of pharyngeal NG infections
Number of subjects: 221
Study 35820778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of vaginal NG infections
Number of subjects: 221
Study 35820778 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous clearance of urethral NG infections
Number of subjects: 221
Study 35820778 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time to spontaneous clearance for pharyngeal infections
Number of subjects: 221